

- Endothelin, in hemostasis, 116
- Endothelium
 anticoagulant activities of, 121f
 anticoagulant effects of, 121
 antithrombotic properties of, 121
 corneal, 1325
 fibrinolytic effects of, 121
 in hemostasis, 121
 leukocyte adhesion to, 75-76
 platelet inhibitory effects of, 121
 in response to injury, 486
- Endotoxin, bacterial, 350
- Endovascular stenting, 520-521
- Energy balance, regulation of, 444, 445f, 446f
- Engulfment, in phagocytosis, 78-79, 80f
- Enteritis associated arthritis, 1213
- Enterochromaffin cells, 1105
- Enterococcal infections, 364-365, 365b
- Enterocolitis
 infectious, 785-796, 786t
 due to *Campylobacter*, 786-787, 787b, 788f
 due to cholera, 785-786, 787f
 due to *Escherichia coli*, 790-791
 due to salmonellosis, 788-789
 due to shigellosis, 787-788, 788b
 due to typhoid fever, 789, 789b
 due to Whipple disease, 791-792, 792b, 792f
 due to *Yersinia*, 789-790, 790b
 parasitic, 794-796
 pseudomembranous, 791, 791b, 791f
 viral, 792-794, 793f
 necrotizing, 459, 460f, 780
 radiation, 780
- Entrapment neuropathy. *See* Compression neuropathy.
- Environment, definition of, 403
- Environmental carcinogens, 278
- Environmental diseases, 403-450
 alcohol, effects of, 417-419
 climate change, health effects of, 405-406, 405f
 definition of, 403-404
 due to thermal injury, 426-427
 electrical injury, due to, 427-428
 global disease burden, effects on, 404-405, 404f
 ionizing radiation, injury produced by, 428-432, 429b
 occupational health risks, due to, 413-417, 414t
 pollution, due to, 407-413, 410b
 air, 407-410
 metals, 410-413
 therapeutic drugs and drugs of abuse, injury by, 419-425
 tobacco, effects of, 414-417, 415f, 415t
 toxicity of chemical and physical agents, due to, 406-407, 407f, 408f
- Environmental hazards, toxicity of, 406
- Environmental influences, of congenital anomalies, 454-455
- Environmental toxins, and breast cancer, 1053-1054
- Enzyme defects, disorders associated with, 149-157
- Enzymes, 1186-1187
 in immediate hypersensitivity, 203
- Eosinophil(s)
 in chronic inflammation, 96-97, 97f
 in immediate hypersensitivity, 204
- Eosinophilia, in inflammation, 99
- Eosinophilic cystitis, 962
- Eotaxin, 87
- Ependymal cells, response to injury of, 1254
- Ependymal granulations, 1254
- Ependymoma, 1310-1311, 1310b-1311b, 1311f
- Ephelis, 1143-1144
- Epicardial coronary arteries, 525
- Epidemic typhus, 384
- Epidermal appendages, disorders of, 1172-1174
 acne vulgaris, 1172-1173
 rosacea as, 1173-1174
- Epidermal growth factor (EGF), 19, 19t
- Epidermal maturation, disorders of, 1161-1162
- Epidermal tumors, premalignant and malignant, 1154-1157, 1157b-1158b
 actinic keratosis as, 1154
 basal cell carcinoma, 1155-1157
 squamous cell carcinoma as, 1155
- Epidermodysplasia verruciformis, 1155
- Epidermolysis bullosa, 1171, 1173f
- Epididymis, inflammation of, 973-974, 974f
- Epididymitis, nonspecific, 973-974, 974b, 974f
- Epidural hematoma, 1261, 1261f, 1262f
- Epigenetic changes, in cancer, 319-320
- Epigenetics, 180
- Epigenome, in cancer, 320
- Epineurium, 1227-1228
- Epispadias, 970
- Epithelial basement membranes, invasion of, by tumor cells, 307f
- Epithelial cell injury, in glomerular disease, 908, 908f
- Epithelial cells, 186
- Epithelial hyperplasia, of breast, 1049, 1049f
- Epithelial-to-mesenchymal transition (EMT), in metastasis, 309
- Epithelial tumors
 benign, 1151-1152
 acanthosis nigricans as, 1151
 epithelial cyst (wen) as, 1152
 fibroepithelial polyp as, 1152
 seborrheic keratoses, 1151
- Epithelioid cells, 97
- Epithelioid hemangioendothelioma, 519, 875
- Epithelium, alveolar, 670
- Epitope spreading, 217
- Epstein-Barr virus (EBV), 360-362
 in Burkitt lymphoma, 327, 327f, 362
 clinical features of, 362
 in immune response, 191
 morphology of, 361b-362b
 oncogenic potential of, 327-328
 pathogenesis of, 360-362, 361f
- ERBB1 gene, 285
- ERBB2 gene, 285, 318
- Erosion, 1143t
- Erysipelas, 365b, 365f
- Erythema, 115
 infectiousum, perinatal infection with, 460, 460f
 multiforme, 1164, 1165f
- Erythroblastosis fetalis, 462b-463b, 463f
- Erythrocyte sedimentation rate, 99
- Erythroid precursors, in hemolytic anemia, 632, 632f
- Erythromelalgia, 620
- Erythroplakia, of oral cavity, 731, 731b, 731f
- Erythropoiesis, anemias of diminished, 630t, 645-655
 aplastic, 653-655, 653t, 654f
 of chronic disease, 652-653
 due to chronic renal failure, 655
 due to hepatocellular liver disease, 655
 due to pure red cell aplasia, 655
 of folate deficiency, 645t, 648-649
 iron deficiency, 649-652, 649t, 650f, 651f
 megaloblastic, 645-648, 645t, 646f
 myelophthisic, 655
 pernicious (vitamin B₁₂ deficiency), 645-647, 645t
- Escherichia coli*, in pyogenic osteomyelitis, 1195
- E-selectin, in inflammation, 76, 76t
- Esophageal atresia, 750, 750f
- Esophageal lacerations, 754, 754t
- Esophageal mucosal webs, 753
- Esophageal obstruction, 753
 eosinophilic, 755f, 756
- Esophageal stenosis, 753
- Esophageal tumors, 758
 adenocarcinomas as, 758, 758b, 759f
 squamous cell carcinoma as, 759-760, 759f
- Esophageal varices, 514, 756-757, 756b, 756f
- Esophagitis, 754-760
 chemical and infectious, 754-755, 754b-755b, 755f
 due to lacerations, 754, 754t
 reflux, 755-756, 755f
- Esophagus, 753-760
 achalasia of, 753-754
 agenesis of, 750
 Barrett, 757-758, 757b, 757f, 758f
- Essential thrombocytosis (ET), 619-620, 620f
- Esthesioneuroblastoma, 737
- Estrogen exposure, and breast cancer, 1053
- Estrogen receptors (ER), in breast carcinoma, 1052, 1068
- État cibl , 1267
- Ethanol
 CNS toxicity of, 1305
 effects of, 417
 metabolism of, 418f
- ETS genes, in prostate cancer, 985
- Euchromatin, 4f
- Euploid, 159
- Ewing sarcoma family tumors, 1203, 1203b, 1203f, 1207b
- Excoriation, 1143t
- Executioner caspases, 56
 in apoptosis, 302
- Exercise, and breast cancer, 1053
- Exocytosis, 9, 1143t
- Exogenous pyrogens, 99
- Exostosis, 1200
- Exotoxins, bacterial, 350-351
- Exstrophy, of bladder, 962, 962f
- External elastic lamina, of blood vessels, 484-485
- External herniation, 777
- Extra-adrenal paragangliomas, familial syndromes associated with, 1134t
- Extracellular matrix (ECM)
 components of, 21-23, 22f
 enzymes in, in angiogenesis, 105
 interaction with, 20-24, 21f
 invasion of, in metastasis, 306-308
 proteins, in angiogenesis, 105